

TG THERAPEUTICS, INC.  
Form 8-K/A  
June 22, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 22, 2015**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**001-32639**

**36-3898269**

(Commission File Number) (IRS Employer Identification No.)

**3 Columbus Circle, 15<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..                   Written communications pursuant to Rule 425 under the Securities Act.
- ..                   Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01. Other Events.**

**Explanatory Note**

This Form 8-K/A is filed by TG Therapeutics, Inc. (“TG” or the “Company”) to correct Item 8.01 of the Current Report on Form 8-K dated June 18, 2015, which referenced a press release announcing updated clinical results from its Phase 2 study of TG-1101 (ublituximab) in combination with ibrutinib. In the release issued on June 18, 2015, the percentage of high-risk CLL patients achieving a confirmed or unconfirmed Complete Response (CR) and/or Minimal Residual Disease (MRD) negativity by the end of the study period (month 6) was incorrectly reported as 20%, when the correct percentage is 25% or 5 of 20 patients. This error appeared in the second bulleted subheading of the release as well as in the third sentence of the first paragraph under the section header “Clinical Activity of TG-1101 + ibrutinib.” Again, the correct statement is 25% of high-risk CLL patients achieved a confirmed or unconfirmed Complete Response (CR) and/or Minimal Residual Disease (MRD) negativity by the end of the study period (month 6). A copy of the revised press release is being filed as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements And Exhibits.**

(d)Exhibits.

99.1 Revised Press Release, revised as of June 22, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**  
(Registrant)

Date: June 22, 2015 By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer

INDEX TO EXHIBITS

**Exhibit  
Number** **Description**

99.1 Revised Press Release, revised as of June 22, 2015